Bladder Cancer, Clinical Trials, Kidney Cancer, Medical Oncology , Pain and Palliative Care - Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology, Urology
Dr. Michael Carducci is a professor of urology and oncology at the Johns Hopkins School of Medicine. He is co-leader of the Prostate Cancer / Genitourinary Oncology Program and co-leader of the Chemical Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr. Carducci received his undergraduate degree from Georgetown University and his medical degree from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at The Johns Hopkins Hospital.
A translational researcher, Dr. Carducci directs a laboratory program focused on the re-expression of epigenetically silenced genes in cancer cells via the use of small molecules targeting DNA methyltransferases and histone deacetylases, and manages a portfolio of clinical trials targeted at introducing these small molecules into cancer treatment. Overall, his laboratory and clinical research focus is on the development and evaluation of new therapies for urologic cancers.
A fellow of the American College of Physicians, Dr. Carducci is a member of several professional organizations, including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and American Urological Association (AUA). Dr. Carducci serves as the principal investigator for a number of National Cancer Institute-supported clinical trials and leads the Johns Hopkins site for the Department of Defense Prostate Cancer Clinical Trials Consortium grant. In addition, he has received peer-reviewed funding for his laboratory and clinical research from the Department of Defense and the Prostate Cancer Foundation.
He is the chair of the Prostate Cancer Subcommittee of the Genitourinary Oncology Committee of ECOG and serves as an alternate to the GU Steering Committee for the National Cancer Institute. Dr. Carducci is also a full member of the Investigational Drug Steering Committee for the NCI. Within ASCO, he is currently chair of the Scientific Program Committee and has previously served on the Cancer Education, Scientific Program and Grants Selection Committees.